1. Silencing of endo-exonuclease expression sensitizes mouse B16F10 melanoma cells to DNA damaging agents

   • Sibgat A. Choudhury
   • Paul Kauler
   • Terry Y-K Chow

   PRECLINICAL STUDIES 11 May 2007 Pages: 399 - 410

   

2. Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide

   • Nicole Wiedenmann
   • Masashi Koto
   • Kathryn A. Mason

   PRECLINICAL STUDIES 11 May 2007 Pages: 411 - 416

   

3. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression

   • Axel-Rainer Hanauske
   • Ulrike Eismann
   • Clet Niyikiza

   PRECLINICAL STUDIES 30 May 2007 Pages: 417 - 423

   

4. Dimethylamino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs: synthesis and cytotoxicity studies

   • Thomas Hickey
   • James Claffey
   • Matthias Tacke

   PRECLINICAL STUDIES 22 May 2007 Pages: 425 - 433

   

5. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin

   • Viktor Horváth
   • Karel Souček
   • Alois Kozubík

   PRECLINICAL STUDIES 23 May 2007 Pages: 435 - 443

   

6. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

   • Charles J. Ryan
   • Walter M. Stadler
   • Eric J. Small

   PHASE I STUDIES 26 April 2007 Pages: 445 - 451

   

7. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

   • Jérôme Alexandre
   • Carmen Kahatt
   • Esteban Cvitkovic

   PHASE I STUDIES 13 July 2007 Pages: 453 - 462

8. Docetaxel–ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines

   • Christos Kosmas
   • Nicolas Tsavaris
   • Athanasios Karabelis

   PHASE II STUDIES 17 March 2007 Pages: 463 - 470

9. Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

   • Jennifer J. Knox
   • Sebastien J. Hotte
   • Elizabeth A. Eisenhauer

   PHASE II STUDIES 28 March 2007 Pages: 471 - 477

10. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study

    • Carlo Carnaghi
    • Armando Santoro
    • Isabella Garassino

    PHASE II STUDIES 11 May 2007 Pages: 479 - 485

    

11. Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors

    • Darren R. Feldman
    • G. Varuni Kondagunta
    • Robert J. Motzer

    PHASE II STUDIES 23 May 2007 Pages: 487 - 490

12. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines

    • Michela Biancolella
    • Alessandra Valentini
    • Giuseppe Novelli

    SHORT REPORT 18 July 2007 Pages: 491 - 497

    

13. Amrubicin for non-small-cell lung cancer and small-cell lung cancer

    • Takayasu Kurata
    • Isamu Okamoto
    • Masahiro Fukuoka

    Review 13 July 2007 Pages: 499 - 504